Search Results - "Tan, Liesbet"

Usage Pattern of Carbamazepine and Associated Severe Cutaneous Adverse Reactions in Singapore Following Implementation of HLA-B15:02 Genotyping as Standard-of-Care by Sung, Cynthia, Tan, Liesbet, Limenta, Michael, Ganesan, Ganga, Toh, Dorothy, Chan, Cheng Leng

“…In April 2013, the Ministry of Health and Health Sciences Authority of Singapore jointly issued recommendations for genotyping before starting carbamazepine…”
Get full text

Hepatotoxic potential of asarones: in vitro evaluation of hepatotoxicity and quantitative determination in herbal products by Patel, Dhavalkumar N, Ho, Han K, Tan, Liesbet L, Tan, Mui-Mui B, Zhang, Qian, Low, Min-Yong, Chan, Cheng-Leng, Koh, Hwee-Ling

“…α and β asarones are natural constituents of some aromatic plants, especially species of the genus Acorus (Araceae). In addition to reports of beneficial…”
Get full text

Are educational materials on medicinal products reaching out and useful to physicians? A survey of Singapore prescribers’ experiences and preferences by Han, Phey-Yen, Limenta, Michael, Tan, Liesbet Li-Bei, Ho, Christine Su-Ching, Poh, Jalene Wang-Woon

“…Background: Effective benefit–risk communication to healthcare professionals plays a vital role in promoting the rational use of medicinal products. The Health…”
Get full text

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach by Tan-Koi, Wei Chuen, Sung, Cynthia, Chong, Yong Yeow, Lateef, Aisha, Pang, Shiu Ming, Vasudevan, Archana, Aw, Derrick, Lui, Nai Lee, Lee, Shan Xian, Ren, Ee Chee, Koay, Evelyn SC, Tay, Yong Kwang, Lim, Yen Loo, Lee, Haur Yueh, Dong, Di, Loke, Celine, Tan, Liesbet, Limenta, Michael, Lee, Edmund JD, Toh, Dorothy, Chan, Cheng Leng

“…The Health Sciences Authority launched a pharmacogenetics initiative in 2008 to facilitate evaluation of pharmacogenetics associations pertinent for Chinese,…”
Get full text

Development of Post-Marketing Risk Management Plan Requirements: The Singapore Experience by Tan, Liesbet Li-Bei, Ho, Christine Su-Ching, Han, Phey-Yen, Chan, Cheng-Leng

“…Historically, global drug safety regulations were generally reactive and post-marketing safety monitoring comprised mainly spontaneous adverse event reporting…”
Get full text

Pharmacogenetic Risk for Adverse Reactions to Irinotecan in the Major Ethnic Populations of Singapore: Regulatory Evaluation by the Health Sciences Authority by Sung, Cynthia, Lee, Pui Ling, Tan, Liesbet L., Toh, Dorothy S.L.

“…Background: For genetic polymorphisms known to alter drug effect or safety, regulatory authorities can tap into population genomic databases and other sources…”
Get full text

Singapore Pharmacogenomics Portal: a web resource for evaluating human genetic variations of genes responsible for drug responses by Wong, Lai-Ping, Poh, Wan-Ting, Chan, Sze-Ling, Tan, Liesbet L, Toh, Dorothy S.-L, Chia, Kee-Seng, Sung, Cynthia, Teo, Yik-Ying

“…The Singapore Pharmacogenomics Portal is the first genomics web platform that links public resources from PharmGKB and DrugBank with population genetics data…”
Get full text

Introduction to risk management plans in the Singapore context by Ho, Christine Su Ching, Tan, Liesbet Li Bei, Chan, Cheng Leng

“…A risk management plan (RMP) contains an overview of important safety concerns associated with the use of a therapeutic product (TP) and proposed…”
Get full text

Lamotrigine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Singapore: A case series by Hui, Laura L Y, Loke, Celine, Aw, Derrick C W, Tan, Liesbet, Limenta, Lie Michael George, Shen, Meixin, Ren, Ee Chee, Toh, Dorothy S L, Lee, Edmund Jon Deoon, Pang, Shiu Ming

Get more information

Pharmacogenetic Risk for Adverse Reactions to Irinotecan in the Major Ethnic Populations of Singapore by Sung, Cynthia, Lee, Pui Ling, Tan, Liesbet L, Toh, Dorothy SL

“…Background: For genetic polymorphisms known to alter drug effect or safety, regulatory authorities can tap into population genomic databases and other sources…”
Get full text

Adverse events associated with the use of complementary medicine and health supplements: An analysis of reports in the Singapore Pharmacovigilance database from 1998 to 2009 by Patel, Dhavalkumar Narendrabhai, Low, Wai-Ling, Tan, Libei Liesbet, Tan, Mui-Mui Belinda, Zhang, Qian, Low, Min-Yong, Chan, Cheng-Leng, Koh, Hwee-Ling

“…Context. The use of complementary and alternative medicine (CAM), particularly herbal medicine and their derived products, have been increasing. However,…”
Get full text